Curaleaf International Acquires Can4Med, Expanding Presence in Poland's Growing Medical Cannabis Market

LONDON, Feb. 6, 2024 – PRESS RELEASE – Curaleaf International, part of Curaleaf Holdings and Europe's largest vertically integrated cannabis company, is pleased to announce its acquisition of Can4Med, a prominent pharmaceutical wholesaler specializing in cannabinoid medications in Poland.

This strategic move marks a significant milestone for both companies and underscores Curaleaf's commitment to enhancing patient access to high-quality medical cannabis products across Europe. Poland boasts one of Europe's largest patient populations seeking medical cannabis; by joining forces with Can4Med, Curaleaf International gains a strong foothold in this dynamic market, allowing it to serve patients more effectively and expand its product offerings.

"This acquisition represents a significant step forward for Curaleaf International. Poland's medical cannabis market is expanding rapidly, and our partnership with Can4Med allows us to better serve patients while driving growth across Europe," Curaleaf CEO Matt Darin said.

"We are thrilled that Can4Med, a pioneering force in Poland's cannabis market, has joined forces with Curaleaf, the global leader in cannabis,” Can4Med founder Maximilian Weinberg said. “This acquisition marks a significant milestone in our journey, ensuring an unparalleled supply chain that positions us to meet and exceed the demands of the entire Polish market. Partnering with Curaleaf not only reinforces our commitment to quality and accessibility but also signifies a new era of growth and possibilities for both companies and our customers."

As Poland positions itself at the forefront of the European cannabis market, its substantial population of 38 million is poised to catalyze significant growth and innovation in the sector. The Polish Pharmaceutical Chamber estimates that the potential number of medical cannabis users could reach 300,000, while the number of legal cannabis users (both medical and CBD) is expected to reach 1.3 million by 2026.

In 2023 alone, the country witnessed a remarkable surge in medical cannabis adoption, with over 3,000 kilograms distributed in Poland, reflecting a growing acceptance and recognition of its therapeutic benefits. This development is supported by an extensive network of medical professionals authorized to prescribe cannabis.

Despite the complex registration process that producers and patients must navigate, Curaleaf International, through its subsidiary Four 20 Pharma GmbH, has emerged as a leading force, securing its position as one of the only licensed producers in the Polish market. This exclusive status underscores Curaleaf's strategic foresight and commitment to meeting the rigorous compliance and quality standards required to operate in this burgeoning market, setting a benchmark for excellence and reliability in the European cannabis industry.